OncoQuest Inc., a biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, announced positive results from its pre-clinical pharmacology studies using its Anti-MUC1 antibody, MAb AR20.5, against pancreatic cancer in a human MUC1 expressing transgenic mouse model. The pre-clinical studies are being conducted at the Eppley Institute for Cancer and Allied Disease at the University of Nebraska Medical Center, under the direction of Dr. Michael Hollingsworth. The results will be presented at the upcoming AACR Special Conference on Tumor Immunology and Immunotherapy in Boston in October of 2016.

The author of the abstract, Dr. Kamiya Mehla, has won a Scholar-in-Training Award based on the quality of the abstract.

 

Read full press release details.